4LOY

Crystal Structure Analysis of thrombin in complex with compound D57, 5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2- oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1- yl)-3-oxopropyl]amide (SAR107375)

Summary for 4LOY

• Entry DOI: 10.2210/pdb4loy/pdb
• Descriptor: Thrombin heavy chain, Hirudin variant-2, Thrombin light chain, ... (7 entities in total)
• Functional Keywords: serine proteases, dual thrombin/factor xa inhibition, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
• Biological source: Homo sapiens (human); More
• Total number of polymer chains: 3
• Total formula weight: 35033.81

Authors

Stehlin-Gaon, C.,Bocskei, Z. (deposition date: 2013-07-14, release date: 2014-06-04, Last modification date: 2024-11-20)

Primary citation

Meneyrol, J.,Follmann, M.,Lassalle, G.,Wehner, V.,Barre, G.,Rousseaux, T.,Altenburger, J.M.,Petit, F.,Bocskei, Z.,Schreuder, H.,Alet, N.,Herault, J.P.,Millet, L.,Dol, F.,Florian, P.,Schaeffer, P.,Sadoun, F.,Klieber, S.,Briot, C.,Bono, F.,Herbert, J.M.
5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.
J.Med.Chem., 56:9441-9456, 2013

PubMed Abstract: Compound 15 (SAR107375), a novel potent dual thrombin and factor Xa inhibitor resulted from a rational optimization process. Starting from compound 14, with low factor Xa and modest anti-thrombin inhibitory activities (IC50's of 3.5 and 0.39 μM, respectively), both activities were considerably improved, notably through the incorporation of a neutral chlorothiophene P1 fragment and tuning of P2 and P3-P4 fragments. Final optimization of metabolic stability with microsomes led to the identification of 15, which displays strong activity in vitro vs factor Xa and thrombin (with Ki's of 1 and 8 nM, respectively). In addition 15 presents good selectivity versus related serine proteases (roughly 300-fold), including trypsin (1000-fold), and is very active (0.39 μM) in the thrombin generation time (TGT) coagulation assay in human platelet rich plasma (PRP). Potent in vivo activity in a rat model of venous thrombosis following iv and, more importantly, po administration was also observed (ED50 of 0.07 and 2.8 mg/kg, respectively). Bleeding liability was reduced in the rat wire coil model, more relevant to arterial thrombosis, with 15 (blood loss increase of 2-fold relative to the ED80 value) compared to rivaroxaban 2 and dabigatran etexilate 1a.

PubMed: 24175584
DOI: 10.1021/jm4005835

Experimental method

X-RAY DIFFRACTION (1.77 Å)